News
Press Releases
Dec 5, 2022
POC efficacy data in rodents shows that a novel adeno-associated virus (AAV) pancreatic gene therapy platform can confer dose-dependent effects on improving insulin production and reducing blood sugar Dose-depend...
Read MoreNov 2, 2022
Newly formed Erase T2D task force comprises leading scientists and pioneering scientific research to elucidate the role of the duodenum in type 2 diabetes and metabolic control Fractyl Health-supported research pr...
Read MoreMay 22, 2022
Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes
Patients treated with Revita experienced a 0.8%-point reduction in HbA1c along with a 33% improvement in markers of insulin sensitivity three months after undergoing the procedure Markers of insulin production cap...
Read MoreMay 17, 2022
Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022
Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Diseas...
Read MoreApr 4, 2022
Revitalize-2 is the second pivotal study for the Revita DMR® system (Revita®) in Fractyl Health’s Revitalize T2D clinical development program Revitalize T2D is designed to evaluate the potential of Revita i...
Read MoreFeb 8, 2022
Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR® System
The Revita DMR System (Revita) gains reimbursement authorization from the German Institute for Hospital Remuneration (InEK) with a NUB Status 1 designation NUB Status 1 entitles participating hospitals in German...
Read MoreFeb 1, 2022
REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of impro...
Read MoreJan 18, 2022
Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di
Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today initial interim feasibility data from human clinical experie...
Read MoreJan 12, 2022
Fractyl Health Appoints Kelly Barnes to the Company’s Board of Directors
Fractyl Health, an organ editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), today announced the appointment of Kelly Barnes to the company’s board of ...
Read MoreNov 30, 2021
Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size
LEXINGTON, Mass., November 30, 2021 - Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today the United States Food...
Read MoreThe press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Fractyl Health disavows any obligation to update the information contained in such press releases after the date of their issuance.
Media Contact: Nancye Green, Fractyl Health,
ngreen@fractyl.com, +1 (917) 273-3536
In the News
Feb 8, 2022
Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR® System
Read MoreFeb 1, 2022
Read MoreMay 21, 2021
How Fractyl is ‘reversing’ type 2 diabetes to reduce or eliminate insulin injections
Drug Delivery Business News
Read MoreApr 27, 2021
Fractyl gets FDA breakthrough nod for intestinal resurfacing in type 2 diabetes
BioWorld
Read MoreMar 22, 2021
Will Fractyl be Successful in Eliminating the Need for Daily Insulin?
MDDI Online
Read More